VIRX (Viracta Therapeutics) Other Financing: $0.04 Mil (TTM As of Sep. 2024)


What is Viracta Therapeutics Other Financing?

Viracta Therapeutics VIRX Other Financing is $0.04 Mil as of Sep. 2024.

Viracta Therapeutics's Other Financing for the three months ended in Sep. 2024 was $0.00 Mil.

Viracta Therapeutics's Other Financing for the trailing twelve months (TTM) ended in Sep. 2024 was $0.04 Mil.

Viracta Therapeutics Other Financing Historical Data

* Premium members only.

The historical data trend for Viracta Therapeutics's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viracta Therapeutics Other Financing Chart

Viracta Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Other Financing
0.00 0.34 0.23 0.14

Viracta Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.04 0.00

Viracta Therapeutics Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of $0.04 Mil mean?
Viracta Therapeutics (VIRX) has a Other Financing of $0.04 Mil as of Sep. 2024. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Viracta Therapeutics and its competitors.
Is Viracta Therapeutics' Other Financing too high?
Viracta Therapeutics' current Other Financing is $0.04 Mil.
How does Viracta Therapeutics' Other Financing compare to TSOI and CYTOF?
Viracta Therapeutics' Other Financing of $0.04 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Viracta Therapeutics and its competitors. Viracta Therapeutics's current Other Financing is $0.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viracta Therapeutics stock overvalued right now?
Viracta Therapeutics (VIRX) has a current Other Financing of $0.04 Mil. The current Other Financing is $0.04 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Viracta Therapeutics (VIRX), the current Other Financing is $0.04 Mil as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Viracta Therapeutics Business Description

Address 2533 South Coast Highway 101, Suite 210, Cardiff, CA, USA, 92007
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.